Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of "Moderate Buy" by Analysts
Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) have received an average recommendation of "Moderate Buy" from the ten brokerages that are currently covering the firm, MarketBeat...